Literature DB >> 12270860

Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis.

Maria C Cid1, José Hernández-Rodríguez, María-José Esteban, Mireia Cebrián, Yong Song Gho, Carme Font, Alvaro Urbano-Márquez, Josep M Grau, Hynda K Kleinman.   

Abstract

BACKGROUND: Vascular inflammatory lesions from patients with giant-cell arteritis show a remarkable amount of neovascularization, but its clinical implications have never been investigated. METHODS AND
RESULTS: To assess the clinical relevance of neovascularization in giant-cell arteritis, angiogenesis was measured in temporal artery sections from 31 patients with biopsy-proven giant-cell arteritis by staining endothelial cells with Ulex europaeus lectin. Angiogenesis was highly variable among these patients. Patients without ischemic complications had higher tissue angiogenesis scores than patients with ischemic events (5.69+/-0.6 versus 2.91+/-0.6, P=0.003). Angiogenesis was also more prominent in patients with a strong acute phase response (score: 5.31+/-0.6) compared with those with a weak systemic inflammatory reaction (2.30+/-0.44; P=0.0007). Serum angiogenic activity was studied in an additional series of 38 biopsy-proven patients. Sera from patients without ischemic events tended to be more active in stimulating human umbilical vein endothelial cell growth (optical density x1000, 270+/-15 versus 192+/-14, P=0.065) and differentiation into capillary-like structures (107+/-5 versus 84+/-8 relative units, P=0.0058) than patients with ischemic complications. Sera from patients without ischemic events had more in vivo full angiogenic activity tested in the chick chorioallantoic membrane than sera from patients with ischemic complications.
CONCLUSION: Inflammation-induced angiogenic activity may play a compensatory role for ischemia in patients with giant-cell arteritis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12270860     DOI: 10.1161/01.cir.0000030185.67510.c0

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  18 in total

Review 1.  Endothelial cells, antineutrophil cytoplasmic antibodies, and cytokines in the pathogenesis of systemic vasculitis.

Authors:  Maria C Cid; Marta Segarra; Ana García-Martínez; Jose Hernández-Rodríguez
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

2.  The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD.

Authors:  Giovana S Di Marco; Stefan Reuter; Uta Hillebrand; Susanne Amler; Maximilian König; Etienne Larger; Hans Oberleithner; Eva Brand; Hermann Pavenstädt; Marcus Brand
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

Review 3.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 4.  Visual loss and other cranial ischaemic complications in giant cell arteritis.

Authors:  Alessandra Soriano; Francesco Muratore; Nicolò Pipitone; Luigi Boiardi; Luca Cimino; Carlo Salvarani
Journal:  Nat Rev Rheumatol       Date:  2017-07-06       Impact factor: 20.543

5.  A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARγ to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction.

Authors:  Dan-yan Xu; Benjamin B Davis; Zhen-he Wang; Shui-ping Zhao; Binaya Wasti; Zhe-liang Liu; Ning Li; Christophe Morisseau; Nipavan Chiamvimonvat; Bruce D Hammock
Journal:  Int J Cardiol       Date:  2012-04-21       Impact factor: 4.164

Review 6.  [Clinical and serological findings of giant-cell arteritis].

Authors:  P Vaith; K Warnatz
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372

7.  Gelatinase expression and proteolytic activity in giant-cell arteritis.

Authors:  Marta Segarra; Ana García-Martínez; Montse Sánchez; José Hernández-Rodríguez; Ester Lozano; Josep M Grau; Maria C Cid
Journal:  Ann Rheum Dis       Date:  2007-05-14       Impact factor: 19.103

8.  Acute effects of prostaglandin E1 and E2 on vascular reactivity and blood flow in situ in the chick chorioallantoic membrane.

Authors:  D R Harland; L D Lorenz; K Fay; B E Dunn; S K Gruenloh; J Narayanan; E R Jacobs; M Medhora
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2012-08-02       Impact factor: 4.006

9.  Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Authors:  Atsushi Ogata; Toshio Tanaka
Journal:  Int J Rheumatol       Date:  2012-01-18

10.  Macrophages and angiogenesis in rheumatic diseases.

Authors:  Nicola Maruotti; Tiziana Annese; Francesco Paolo Cantatore; Domenico Ribatti
Journal:  Vasc Cell       Date:  2013-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.